Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study

Journal of Clinical Oncology

Volumn 19, Issue 6, 2001, Pages 1750-1758

  Schuler, M ^a   Herrmann, R ^a   De Greve, J L P ^a   Stewart, A K ^a   Gatzemeier, U ^a   Stewart, D J ^a   Laufman, L ^a   Gralla, R ^a   Kuball, J ^a   Buhl, R ^a   Heussel, C P ^a   Kommoss, F ^a   Perruchoud, A P ^a   Shepherd, F A ^a   Fritz, M A ^a   Horowitz, J A ^a   Huber, C ^a   Rochlitz, C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; NAVELBINE; PACLITAXEL; PROTEIN P53; SCH 58500; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; GENE THERAPY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TRANSGENE; TUMOR BIOPSY;

EID: 0035868848     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.6.1750     Document Type: Article

References (41)

1. Cancer statistics
2. p53: A frequent target for genetic abnormalities in lung cancer
3. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer
4. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers
5. bcl-2 and p53 protein expression in non-small cell lung cancers: Correlation with survival time
6. p53, the cellular gatekeeper for growth and division
7. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
8. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model
9. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer
10. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts
11. Recombinant El-deleted adenovirus-mediated gene therapy for cancer: Efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models
12. Adenovirally transferred p16 INK4/CDKN 2 and p53 genes cooperate to induce apoptotic tumor cell death
13. Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein
14. A novel adenoviral vector expressing human Fas/CD95/APO-1 enhances p53-mediated apoptosis
15. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
16. A phase I study of adenovirus mediated wild type p53 gene transfer in patients with advanced non-small cell lung cancer
17. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer
18. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer
19. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography
20. CT-guided intratumoral gene therapy in non-small cell lung cancer
21. Comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenovital infectivity and p53 protein expression in gene therapy
22. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles
23. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene
24. Wild-type p53 mediates apoptosis by EIA, which is inhibited by EIB
25. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia
26. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
27. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and heck squamous cell carcinoma
28. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
29. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours
30. Paclitaxel by I-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma
31. Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer
32. Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: A phase II study
33. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
34. p53 tumor suppressor gene therapy for cancer
35. p21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients
36. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
37. ONYX-015, an EIB gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
38. Intratumoral injection of ONYX-015 for gastrointestinal tumors metastatic to the liver: A phase I trial
39. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
40. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwestern Oncology Group study
41. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: Interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group